Jonathan D. Schwartz

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.5K citations

Medicine, Oncology, Pharmacotherapy +13

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Charles S. Fuchs, Jiří Tomášek, Filip Dumitru et al. · The Lancet · 2013 · 2.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Medicine, Oncology, Pharmacology +9

Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

Abby B. Siegel, E. Cohen, Allyson J. Ocean et al. · Journal of Clinical Oncology · 2008 · 510 citations · Full text

Medicine, Oncology, Pharmacology +17

Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis

Sasan Roayaie, Jonathan D. Schwartz, Max W. Sung et al. · Liver Transplantation · 2004 · 463 citations

Medicine, Oncology, Surgery +17